Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.1581 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1581 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0976 | 0.2407 | 0.2407 |
Loa Loa (eye worm) | hypothetical protein | 0.1581 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0797 | 0.0151 | 0.0151 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.1581 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.1581 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1581 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.1581 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.1401 | 0.7743 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.1581 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0785 | 0 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.1581 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.1581 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.1581 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1581 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.1581 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1581 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.1581 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.1581 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.1581 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.1581 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.1581 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.1581 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0976 | 0.2407 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.1581 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0785 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.1581 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.1401 | 0.7743 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
KA (binding) | = 0.71 uM | Activation of transmembrane human carbonic anhydrase-14 incubated for 15 mins prior to testing by stopped-flow CO2 hydrase assay | ChEMBL. | 25082511 |
KA (binding) | = 0.84 uM | Activation of cytosolic human carbonic anhydrase-7 incubated for 15 mins prior to testing by stopped-flow CO2 hydrase assay | ChEMBL. | 25082511 |
KA (binding) | = 0.96 uM | Activation of cytosolic human carbonic anhydrase-12 incubated for 15 mins prior to testing by stopped-flow CO2 hydrase assay | ChEMBL. | 25082511 |
KA (binding) | = 10.9 uM | Activation of cytosolic human carbonic anhydrase-1 incubated for 15 mins prior to testing by stopped-flow CO2 hydrase assay | ChEMBL. | 25082511 |
KA (binding) | = 32 uM | Activation of cytosolic human carbonic anhydrase-2 incubated for 15 mins prior to testing by stopped-flow CO2 hydrase assay | ChEMBL. | 25082511 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.